Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc., as noted in the metadata) on June 11, 2019, covering events occurring on June 7, 2019. The report details the outcomes of the Company's Annual Meeting of Stockholders, including the election of directors, ratification of the independent auditor, and approval of a new employee stock purchase plan.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Director Elections: Stockholders elected Alexis A. Borisy, Blake Byers, Ph.D., and Amy L. Ronneberg as Class I directors for a three-year term ending in 2022.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Employee Stock Purchase Plan (ESPP): Stockholders approved the 2019 ESPP, which allows employees to purchase common stock via payroll deductions. The plan was adopted by the Board on April 18, 2019, and became effective on June 7, 2019.
Voting Results and Implementation Details
Proposal 1: Election of Class I Directors
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Alexis A. Borisy | 12,093,122 | 5,281,718 | 9,691,532 |
| Blake Byers, Ph.D. | 12,458,068 | 4,916,772 | 9,691,532 |
| Amy L. Ronneberg | 12,445,289 | 4,929,551 | 9,691,532 |
Proposal 2: Ratification of Auditor (KPMG LLP)
- Votes For: 26,987,809
- Votes Against: 73,447
- Abstain: 5,116
Proposal 3: Approval of 2019 ESPP
- Votes For: 11,174,897
- Votes Against: 6,179,284
- Abstain: 20,659
- Broker Non-Votes: 9,691,532
The 2019 ESPP is anticipated to be implemented on December 1, 2019, though the Compensation Committee retains the discretion to delay the start date of offerings.
Investor Verification Checklist
- Verify the correct registrant name is Magenta Therapeutics, Inc. (Ticker: MGTA), not Dianthus Therapeutics.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 25, 2019) for detailed terms of the 2019 ESPP.
- Confirm the implementation timeline for the ESPP, noting the potential for delay by the Compensation Committee.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial metrics.